A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (AVONELLE-X)
Latest Information Update: 16 Dec 2024
At a glance
- Drugs Faricimab (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms AVONELLE-X
- Sponsors Roche
Most Recent Events
- 21 Oct 2030 This profile has been reviewed under High Value Profile, Ad Hoc Task.
- 01 Oct 2024 Status changed from active, no longer recruiting to completed.
- 18 Sep 2024 This trial has been completed in Poland (Global end date: 2024-09-03) according to European Clinical Trials Database record.